Senzime is granted additional patent for OnZurf Probe

Senzime has developed user-friendly products for continuous collection and measurement of glucose and lactate in biological fluids such as blood and tissues. These measurements are important and often critical for surgical patients who are at risk of postoperative complications such as ischemia (lack of oxygen) and anastomotic breakdown and leakage (failure of organ connections that lead to tissue death).

CliniSenz system consists of OnZurf Probe and CliniSenz Analyzer. The system makes it possible to continuously collect and analyze samples taken from the surface of an organ. Currently, the OnZurf Probe is used in a study of patients undergoing surgery for esophageal cancer, a surgical procedure that is performed on half a million patients worldwide, every year. In Sweden tens of thousands of cancer operations are performed annually; effective monitoring systems such as the CliniSenz system can help reduce the number of painful and costly complications, improving patient safety and decreasing healthcare costs.

"The granted patents strengthen our patent portfolio for both OnZurf Probe and the complete CliniSenz system. We remain confident that we have highly attractive products and that we are on the right market at the right time. We have signed a breakthrough agreement for the Japanese market, strengthened our organization, we face a broad market introduction, and we look forward to continued effective development in 2017”, says Senzime CEO, Lena Söderström.

For further information, please contact: 

Lena Söderström, CEO

Tel: +46-70-816 39 12 email: lena.soderstrom@senzime.com

TO THE EDITORS  

About Senzime  

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com